46 Months for Counterfeit Botox: What a Federal Med Spa Sentence Means for Florida Injectors and Owners

A Massachusetts med spa owner is going to federal prison for 46 months. She was not a nurse, she bought her Botox and fillers from overseas suppliers, and she kept injecting clients after federal agents seized her shipments, searched both of her locations and arrested her. The sentence came down in Boston on September 2, 2026, along with more than $1 million in restitution and a matching forfeiture judgment.

Florida med spa owners and injectors should read past the headline. The counterfeit product made the case. What made it a four-year case was everything that happened after the government made contact.

The counterfeit product made the case. What made it a four-year case was everything that happened after the government made contact.

Key Takeaways

• A federal court in Boston imposed 46 months for injecting counterfeit Botox and fillers, charged under 18 U.S.C. § 545 and 21 U.S.C. §§ 331 and 333.
• Restitution and forfeiture were each ordered at about $1 million. They are separate judgments, and one does not automatically cancel the other.
• Continuing to inject after customs seizures, a search warrant and an arrest turned a counterfeit product case into a prison case at sentencing.
• In Florida, unlicensed injecting is a felony under Fla. Stat. § 456.065, and serious bodily injury raises it to a second-degree felony.
• A customs seizure notice or FDA detention notice marks the start of a federal investigation. Counsel belongs in the file before anyone responds.

What Happened in the Massachusetts Case

According to the U.S. Attorney's Office for the District of Massachusetts, the defendant was a 40-year-old aesthetician who owned a med spa with two locations south of Boston. She was never licensed to inject or to dispense prescription drugs or devices, but she told clients and staff she was a nurse. She told clients she was using authentic Botox and FDA-approved fillers such as Sculptra, Restylane and Juvéderm. Prosecutors said the product was counterfeit, much of it imported from China and Brazil, and that there was no record she ever bought authentic product from the manufacturers.

Business records showed more than 2,700 injection procedures between March 2021 and June 2024, paid for by more than 900 clients who spent over $1 million. Clients reported infections, drooping and paralysis of the face and eyes, double vision, impaired eyesight and hard nodules under the skin. Several were hospitalized. When agents searched both locations in June 2024, they recovered counterfeit product and bacteriostatic water used to dilute Botox that tested positive for methylobacterium, which can cause infection.

More than 2,700 injection procedures, more than 900 clients, over $1 million in payments. Prosecutors said there was no record she ever bought authentic product from the manufacturers.

She was charged by complaint in November 2024 and pleaded guilty in April 2026 to four counts of importing merchandise contrary to law, two counts of selling or dispensing a counterfeit drug and two counts of selling or dispensing a counterfeit device. The court imposed 46 months in prison and two years of supervised release.

What Drove a Four-Year Sentence

Counterfeit product and false credentials made the case. They did not, by themselves, make it a four-year case. The facts the government pressed at sentencing were about conduct after contact.

After federal authorities began seizing her international shipments and notified her that the products were misbranded and unapproved, prosecutors said she told suppliers to ship to different addresses under other people's names. She kept injecting after the June 2024 searches. She kept injecting until her arrest. Then, in May 2025, while on pretrial release, she performed an injection at her home with an unknown substance the client believed was Sculptra. Her release was revoked under the procedure in 18 U.S.C. § 3148, and she has been in custody since November 2025.

The U.S. Attorney told the press this was no mistake or one-time lapse. Prosecutors make that argument in every sentencing. Here the record let them prove it.

She kept injecting after the June 2024 searches. She kept injecting until her arrest. Then she did it again on pretrial release.

From the defense side, each of those facts closes a door. Rerouting shipments after a seizure notice is the kind of conduct that supports an obstruction enhancement. Continuing the conduct after a search, and again on release, puts acceptance-of-responsibility credit at risk, because the guidelines treat voluntary withdrawal from criminal conduct as part of acceptance. It also takes away the best mitigation argument a med spa client can have: that she stopped the moment she understood the risk.

The Charges and the Sentencing Math

The statutes in play are the same ones FDA's Office of Criminal Investigations brings in every counterfeit injectables case:

• 18 U.S.C. § 545, importing merchandise contrary to law, carries up to 20 years per count.
• 21 U.S.C. § 331(i)(3) and § 333(b)(8), selling or dispensing a counterfeit drug, carry up to 10 years per count. The counterfeit device counts carried the same ten-year maximum.
• 21 U.S.C. §§ 331(a) and 333(a)(2), felony misbranding with intent to defraud or mislead, carries up to three years. The same office used it in a separate med spa case last year involving unapproved botulinum toxin.
• 18 U.S.C. § 1343, wire fraud, is available whenever payments or marketing cross state lines.

Statutory maximums are not the number that matters. The guidelines are. The FDCA guideline, §2N2.1 of the federal sentencing guidelines, sends any offense involving fraud to the fraud guideline, §2B1.1, where the offense level climbs with loss. The fraud guideline also adds levels when the offense involved a conscious or reckless risk of serious bodily injury, and hospitalized victims make that enhancement hard to fight. Add obstruction, subtract little or nothing for acceptance, and a first offender with no record lands in a range measured in years.

In practice, the sentencing guidelines calculation in these cases turns on a loss amount dispute. The government's figure here was gross client payments. There is room to argue that loss should account for the value clients received, procedures that used authentic product, or services with no connection to counterfeit inventory. Those arguments were weak in this case because the government alleged the entire supply was counterfeit. In a case with a mixed supply chain, they can move the range substantially.

The FDCA guideline sends any offense involving fraud to §2B1.1, where the offense level climbs with loss. The loss number is where these cases are fought.

Then there is the money. The court ordered restitution and forfeiture each at $1,001,562. Restitution under 18 U.S.C. § 3663A compensates victims. Forfeiture under 18 U.S.C. § 982 takes proceeds for the government. Forfeited funds reach victims only if the government agrees to apply them through remission or restoration, so a $1 million problem can become a $2 million judgment. That is why asset forfeiture defense belongs in the plan from the first day, not after the plea.

Why This Matters in Florida

This is not only a Massachusetts story. South Florida has a large aesthetics market, international ports that FDA and Customs watch for unapproved drug imports, and prosecutors in state and federal court who treat injection injuries as serious crime.

On the state side, unlicensed practice of a health care profession is a third-degree felony under Fla. Stat. § 456.065, and it becomes a second-degree felony with a one-year minimum when the practice results in serious bodily injury. Practicing medicine without a license is separately criminalized under Fla. Stat. § 458.327. A Port St. Lucie injection case this summer ended in a three-year state prison sentence after a single client reported facial paralysis.

On the federal side, a Florida case would be built the same way as the Massachusetts one. An FDA OCI investigation works the supply chain with Customs, and the Southern District or the Middle District charges it through a health care fraud unit. For Southern District of Florida federal defense, the bridge from a state licensing problem to a federal case is almost always product sourcing. Buying injectables from anyone other than the manufacturer or a licensed distributor is the fact that federalizes the file.

The exposure also reaches past the injector. Owners who never touch a syringe, medical directors whose names are on the protocols, and nurse practitioners who sign off on standing orders can all be drawn in when the product is counterfeit. That is now a routine part of South Florida healthcare fraud defense.

Early Mistakes That Make These Cases Worse

Once a med spa FDA investigation starts, the Massachusetts case reads as a list of what not to do:

• Treating a customs seizure notice as a shipping problem. A seizure or detention notice means federal agents already know your name and your supplier.
• Changing addresses or recipients after a seizure. That is concealment, and it supports obstruction.
• Talking to agents during a search warrant executed at your business. Statements about training, sourcing and credentials become the government's exhibits.
• Continuing to treat patients while under investigation. Every procedure after contact is a new count and a new sentencing fact.
• Contacting injured clients with explanations or offers of more treatment. Prosecutors read that as consciousness of guilt.

What Early Defense Work Can Accomplish

If you are the subject of a federal investigation involving injectables, the useful window is before charges. Pre-indictment defense counsel can stop the conduct that creates new counts, put a litigation hold and a document plan in place, learn whether the government views you as a target or a witness, and open a line to the prosecutor before the charging decision hardens. Where sourcing problems are real, a voluntary stop and a documented move to authentic, traceable product is mitigation that cannot be manufactured later.

If charges are coming, the choice between cooperation and litigation turns on the supply chain. Importers and distributors matter more to prosecutors than a single injector. That leverage exists early and disappears once the government has what it needs.

If the case is headed to sentencing, the work is the loss number, the injury enhancement, acceptance and a documented variance argument under 18 U.S.C. § 3553(a). A federal sentencing attorney can build all four. None of them is available to a client who keeps injecting.

Why Timing Decides These Cases

The Massachusetts defendant had at least four chances to change the direction of her case: the first seizure notice, the searches, the arrest and pretrial release. She used none of them. Most people in her position get one or two.

In Florida, where state and federal investigators share information, the first contact may come from the Department of Health, a code enforcement officer or a customs notice. Treat any of them as the opening of a criminal file and bring in a federal criminal defense attorney while the government is still deciding what the case is.

Common Questions

Facing a Med Spa or FDA Investigation in Florida?

AMC Defense Law represents med spa owners, injectors, nurse practitioners, physician assistants and medical directors in federal and state investigations involving injectables, product sourcing and licensing. As a white collar defense attorney handling federal investigation defense in Florida and nationwide, Aaron M. Cohen works with clients before charges are filed, when the options are widest. If you have received a customs seizure notice, an FDA inquiry or a visit from agents, call before you respond. Consultations are confidential. Call 561.542.5494 or contact the firm through amcdefenselaw.com.

The useful window is before charges. Pre-indictment counsel can stop the conduct that creates new counts and open a line to the prosecutor before the charging decision hardens.

If you or your loved ones are facing a med spa, counterfeit product or FDA investigation in Florida, call Aaron M. Cohen, 24 hours a day to get help.

About the Author

Aaron M. Cohen is the founder of AMC Defense Law, a federal criminal defense firm in Boca Raton, Florida. He is admitted to practice in Florida (Florida Bar No. 541427) and New York, and before the United States District Courts for the Southern District of Florida and the Southern District of New York. The firm represents clients in federal investigations and prosecutions involving healthcare fraud, Anti-Kickback Statute matters, DME and telemedicine fraud, peptide and compounded-drug enforcement, controlled-substance and drug conspiracy cases, financial crimes, and complex federal litigation, in Florida and nationwide.

This article is provided for general informational purposes only and does not constitute legal advice. Reading this article does not create an attorney-client relationship with AMC Defense Law or Aaron M. Cohen. Every case is different, and outcomes depend on specific facts and circumstances. If you are facing an investigation or criminal charges, consult a qualified attorney about your particular situation.